Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial.

医学 二甲双胍 吉非替尼 安慰剂 内科学 临床终点 肺癌 胃肠病学 肿瘤科 随机对照试验 癌症 表皮生长因子受体 胰岛素 病理 替代医学
作者
Yong He,Li Li,Liyan Jiang,Yubo Wang,Yizhuo Zhao,Xiaoju Zhang,Guoming Wu,Xiangdong Zhou,Jianguo Sun,Jun Bai,Biyong Ren,Kun Tian,Zhixiang Xu,Hualiang Xiao,Qi Zhou,Rui Han,Hengyi Chen,Haidong Wang,Zhenzhou Yang,Chan Gao
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:37 (15_suppl): 9035-9035 被引量:2
标识
DOI:10.1200/jco.2019.37.15_suppl.9035
摘要

9035 Background: Several lines of evidence suggested a role for metformin in sensitizing diabetic NSCLC patients to EGFR tyrosine kinase inhibitors (TKIs). However, data regarding its effects on non-diabetic populations remained scarce. We hereby examined metformin’s first-line use alongside gefitinib in EGFR mutation positive (EGFRm) patients without diabetes. Methods: In this trial (NCT01864681), 224 non-diabetic patients with treatment naïve stage IIIB-IV EGFRm NSCLC were randomly assigned at 1:1 to receive gefitinib plus metformin or placebo. Gefitinib was administered at 250 mg once daily, while metformin/placebo was initiated at 500 mg once daily and then escalated to 1000 mg twice daily over 2 weeks. Dose reduction was permitted for metformin/placebo in case of intolerable toxicity. The primary endpoint was progression-free survival (PFS) rate at 1 year. Secondary endpoints were overall survival (OS), PFS, objective response rate (ORR), and safety. Serum levels of interleukin-6 were also subjected to exploratory analysis. Results: Baseline characteristics were well balanced between treatment groups. The median duration of follow-up was 19.15 (IQR 12.99-28.44) months. The estimated 1-year PFS rate was 41.2% (95% confidence interval [CI] 30.0-52.2) in the metformin group versus 42.9% (95% CI 32.6-52.7) in the placebo group (p = 0.6268). Metformin did not increase median PFS (10.3 months vs. 11.4 months), median OS (22.0 months vs. 27.5 months), or ORR (66.0% vs. 66.7%) over placebo. No significant treatment group differences in terms of PFS were detected across subgroups either, including those with elevated levels of interleukin-6. Metformin plus gefitinib shared a similar safety profile with the control group, except for a remarkably higher incidence of diarrhea (78.38% vs. 43.24%). Conclusions: Our study did not show enhanced gefitinib efficacy upon addition of metformin and hence does not support its concurrent use with first-line EGFR-TKI therapy in non-diabetic EGFRm NSCLC patients. Clinical trial information: NCT01864681.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
1秒前
lan2720完成签到 ,获得积分10
1秒前
2秒前
2秒前
白色噪音完成签到,获得积分20
3秒前
4秒前
4秒前
Tuniverse_发布了新的文献求助10
5秒前
5秒前
chengsi完成签到,获得积分10
5秒前
5秒前
5秒前
5秒前
旭东静静发布了新的文献求助10
5秒前
6秒前
6秒前
SciGPT的应助被公孙世往采纳,获得10
6秒前
6秒前
6秒前
6秒前
6秒前
6秒前
有尾的无尾熊完成签到,获得积分10
6秒前
秋风的应助被追寻的钥匙采纳,获得20
7秒前
无极微光的应助被橘子采纳,获得20
7秒前
8秒前
CITY111119发布了新的文献求助10
8秒前
8秒前
9秒前
summer完成签到 ,获得积分10
9秒前
一生所爱发布了新的文献求助10
9秒前
alexwumk发布了新的文献求助10
10秒前
乐观冥幽发布了新的文献求助10
11秒前
呆萌画笔完成签到,获得积分10
11秒前
11秒前
焦哈哈完成签到,获得积分10
12秒前
Aurora发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181892
求助须知:如何正确求助?哪些是违规求助? 9571628
关于积分的说明 21818984
捐赠科研通 7778258
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557720
邀请新用户注册赠送积分活动 2479621